Sex: F
Vaccine: COVID19
Symptoms: Arthritis, Psoriasis
Clinical narrative: Psoriasis aggravated / Plaque psoriasis worsened; Arthritis aggravated / worsening arthritic pain; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Psoriasis aggravated / Plaque psoriasis worsened) and ARTHRITIS (Arthritis aggravated / worsening arthritic pain) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) injection for Plaque psoriasis.    No Medical History information was reported.   On 01-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced PSORIASIS (Psoriasis aggravated / Plaque psoriasis worsened) and ARTHRITIS (Arthritis aggravated / worsening arthritic pain). At the time of the report, PSORIASIS (Psoriasis aggravated / Plaque psoriasis worsened) had not resolved and ARTHRITIS (Arthritis aggravated / worsening arthritic pain) outcome was unknown.            On unknown dates, the patient experienced ineffective response. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Concomitant medications were not reported.  No treatment information was provided by the reporter. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company comment: This spontaneous case concerns an elderly female patient of an unknown age, with no reported medical history, treated with co-suspect Adalimumab for moderate to severe chronic plaque psoriasis, who experienced the unexpected non-serious AESI Arthritis after receiving a dose of mRNA-1273 vaccine. The onset date of event was not reported. The patient experienced worsened plaque psoriasis and worsening arthritic pain. Clinical course and treatment details were not reported. The outcome of event was reported as unknown. Patient received 2 doses of mRNA-1273 vaccine as primary series at an interval of 31 days, then 3rd dose mRNA-1273 vaccine was given after 7 months. The co-suspect Adalimumab could be considered as a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns an elderly female patient of an unknown age, with no reported medical history, treated with co-suspect Adalimumab for moderate to severe chronic plaque psoriasis, who experienced the unexpected non-serious AESI Arthritis after receiving a dose of mRNA-1273 vaccine. The onset date of event was not reported. The patient experienced worsened plaque psoriasis and worsening arthritic pain. Clinical course and treatment details were not reported. The outcome of event was reported as unknown. Patient received 2 doses of mRNA-1273 vaccine as primary series at an interval of 31 days, then 3rd dose mRNA-1273 vaccine was given after 7 months. The co-suspect Adalimumab could be considered as a confounder. The benefit-risk relationship of mRNA-1273 is not affected by this report.